



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

Date: -13th August, 2018

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai - 400 001
BSE Code: 532878

To,
Listing Department,
National Stock Exchange of India Limited.
Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Code: ALPA

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This is to inform you that the Board of Directors of the Company at its meeting held today that is on **Monday 13th August, 2018 at 04.00 P.M. and concluded at 08:20 P.M.** at Registered Office of the Company at Indore. The Board inter-alia has approved the following matter:

1. Approval of Standalone Financial Results of the Company for quarter and period ended 30th June, 2018.

You are requested to take the same on records.

Thanking you,

Yours Faithfully

For ALPA LABORATORIES LIMITED

Mahendera

MS Chawla

Director

DIN No.00362058






**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE
SEBI LODR REGULATIONS, 2015**

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of ALPA LABORATORIES LIMITED for the quarter ended June 30, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
Anuradha Ratnaparkhi & Associates.

Chartered Accountants
Firm Registration No.023451C


Anuradha Ratnaparkhi
Proprietor

Membership Number:075412

Date: August 13,2018

Place: Indore

ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE
(M.P.) 453446
(Rs. In Lacs Unless Otherwise Stated)

Financial Results for Quarter ended on 30th
June 2018

Particulars	Standalone Results			
	Quarter Ended			Year Ended
	Jun-18	Mar-18	Jun-17	Mar-18
	Unaudited			Audited
1. Income				
a) Revenue from operations	1700.87	1790.78	1085.96	6226.82
b) Other Income	110.14	47.78	142.54	451.44
1. Total income from operations (net) (a+b)	1811.01	1838.56	1228.51	6678.26
2. Expenses				
a) Cost of materials consumed	856.26	991.46	611.10	3304.56
b) Purchases of stock-in-trade	20.67	64.89	86.09	226.66
c) Changes in inventories of fin. goods, stock-in-pro. &	136.11	59.24	-114.80	31.07
d) Employee benefits expense	262.11	287.17	240.35	1025.56
e) Finance costs	18.13	15.05	24.29	107.15
f) Depreciation and amortization expense	27.62	32.39	22.79	112.89
g) Other expenses				
Manufacturing & Operating	99.39	85.59	96.82	357.32
(Stores and spares consumed, power & fuel, job work charges contract				
Others	205.30	403.63	137.21	853.32
Total expenses	1625.60	1939.42	1103.85	6018.53
3. Profit/(Loss) before exceptional items and tax (1-2)	185.41	-100.86	124.66	659.73
4. Exceptional Items				
5. Profit/ Loss(-) before tax (3+/-4)	185.41	-100.86	124.66	659.73
6. Tax (Expenses)/ Benefit				
Current tax	18.73	(188.93)	-	-188.93
Deferred tax	-	10.49	-	10.49
7. Profit/ Loss(-) for the period (5-/+6)	204.14	-279.30	124.66	481.29
8. Other Comprehensive Income				
(i) (a) Items that will not be reclassified to profit or loss	-	-	-	-
(b) Tax expense (benefit) on items that will not be reclassified to profit or loss	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-
(b) Tax expense (benefit) on items that will be reclassified to profit or loss	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	-	-
9. Total comprehensive income for the period (7+8)	204.14	-279.30	124.66	481.29
10. Paid-up equity share capital (Face Value '10 Each)	2104.06	2104.06	2104.06	2104.06
11. Other equity (excluding revaluation reserve)	-	-	-	8223.49
12. Debenture Redemption Reserve	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	0.97	(1.33)	0.59	2.29

Notes -

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.

For ALPA Laboratories Ltd
Mahendra
Director
DIN: 00362058

